NVIV
Income statement / Annual
Last year (2022), InVivo Therapeutics Holdings Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, InVivo Therapeutics Holdings Corporation's net income was -$10.18 M.
See InVivo Therapeutics Holdings Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$445.00 K
|
$372.00 K
|
$329.00 K
|
$322.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$445.00 K
|
-$372.00 K
|
-$329.00 K
|
-$322.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.23 M
|
$4.38 M
|
$3.94 M
|
$5.60 M
|
$4.93 M
|
$11.08 M
|
$12.56 M
|
$10.06 M
|
$10.27 M
|
$10.53 M
|
| General & Administrative Expenses |
$5.42 M
|
$5.52 M
|
$5.16 M
|
$5.90 M
|
$7.84 M
|
$13.51 M
|
$11.51 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.42 M
|
$5.52 M
|
$5.16 M
|
$5.90 M
|
$7.84 M
|
$13.51 M
|
$11.51 M
|
$12.34 M
|
$7.57 M
|
$8.47 M
|
| Other Expenses |
$9.00 K
|
$2.00 K
|
$4.00 K
|
$79.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$10.65 M
|
$9.90 M
|
$9.10 M
|
$11.50 M
|
$12.77 M
|
$24.59 M
|
$24.06 M
|
$22.40 M
|
$17.84 M
|
$19.01 M
|
| Cost And Expenses |
$10.65 M
|
$9.90 M
|
$9.10 M
|
$11.50 M
|
$12.77 M
|
$24.59 M
|
$24.06 M
|
$22.40 M
|
$17.84 M
|
$19.01 M
|
| Interest Income |
$151.00 K
|
$3.00 K
|
$19.00 K
|
$255.00 K
|
$0.00
|
$189.00 K
|
$187.00 K
|
$60.00 K
|
$5.00 K
|
$15.28 K
|
| Interest Expense |
$151.00 K
|
$0.00
|
$19.00 K
|
$254.00 K
|
$206.00 K
|
$74.00 K
|
$155.00 K
|
$172.00 K
|
$136.00 K
|
$129.90 K
|
| Depreciation & Amortization |
$445.00 K
|
$372.00 K
|
$329.00 K
|
$988.00 K
|
$12.26 M
|
$395.00 K
|
$553.00 K
|
$689.00 K
|
$752.00 K
|
$740.69 K
|
| EBITDA |
-$9.89 M |
-$9.53 M |
-$8.77 M |
-$10.59 M |
-$23.13 M |
-$26.28 M |
-$22.73 M |
-$32.45 M |
-$17.08 M |
-$19.37 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$160.00 K
|
$5.00 K
|
$23.00 K
|
-$333.00 K
|
-$10.66 M
|
-$3.05 M
|
$625.00 K
|
-$10.92 M
|
-$507.00 K
|
-$19.75 M
|
| Income Before Tax |
-$10.49 M
|
-$9.90 M
|
-$9.07 M
|
-$11.83 M
|
-$23.42 M
|
-$26.75 M
|
-$23.44 M
|
-$33.31 M
|
-$18.35 M
|
-$38.76 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$412.00 K
|
$22.82 M
|
$2.27 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$10.18 M
|
-$9.89 M
|
-$9.06 M
|
-$12.24 M
|
-$46.24 M
|
-$26.75 M
|
-$23.44 M
|
-$33.31 M
|
-$18.35 M
|
-$38.76 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-6.62 |
-7.47 |
-32.8 |
-912.63 |
-3725.45 |
-15221.97 |
-14170.5 |
-23610.21 |
-15587.09 |
-36910.4 |
| EPS Diluted |
-6.62 |
-7.47 |
-32.8 |
-912.63 |
-3725.15 |
-15221.97 |
-14170.5 |
-23610.21 |
-15587.09 |
-36910.4 |
| Weighted Average Shares Out |
$1.54 M
|
$1.32 M
|
$276.11 K
|
$13.41 K
|
$12.41 K
|
$1.76 K
|
$1.65 K
|
$1.41 K
|
$1.18 K
|
$1.05 K
|
| Weighted Average Shares Out Diluted |
$1.54 M
|
$1.32 M
|
$276.11 K
|
$13.41 K
|
$12.41 K
|
$1.76 K
|
$1.65 K
|
$1.41 K
|
$1.18 K
|
$1.05 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
